Reinfeld, Bradley I. http://orcid.org/0000-0003-4161-8301
Madden, Matthew Z. http://orcid.org/0000-0003-4062-4427
Wolf, Melissa M.
Chytil, Anna
Bader, Jackie E.
Patterson, Andrew R.
Sugiura, Ayaka
Cohen, Allison S.
Ali, Ahmed
Do, Brian T. http://orcid.org/0000-0003-4992-2623
Muir, Alexander
Lewis, Caroline A. http://orcid.org/0000-0003-1787-5084
Hongo, Rachel A.
Young, Kirsten L.
Brown, Rachel E.
Todd, Vera M.
Huffstater, Tessa http://orcid.org/0000-0002-7906-807X
Abraham, Abin
O’Neil, Richard T.
Wilson, Matthew H.
Xin, Fuxue
Tantawy, M. Noor
Merryman, W. David http://orcid.org/0000-0001-9662-1503
Johnson, Rachelle W.
Williams, Christopher S.
Mason, Emily F.
Mason, Frank M. http://orcid.org/0000-0003-1338-494X
Beckermann, Katherine E.
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Manning, H. Charles
Rathmell, Jeffrey C. http://orcid.org/0000-0002-4106-3396
Rathmell, W. Kimryn http://orcid.org/0000-0002-4984-0225
Article History
Received: 9 August 2020
Accepted: 10 March 2021
First Online: 7 April 2021
Competing interests
: J.C.R. has held stock equity in Sitryx and within the past two years has received unrelated research support, travel and honoraria from Sitryx, Caribou, Nirogy, Kadmon, Calithera, Tempest, Merck, Mitobridge and Pfizer. Within the past two years, W.K.R. has received unrelated clinical research support from Bristol-Meyers Squib, Merck, Pfizer, Peloton, Calithera and Incyte. H.C.M. holds a patent for V9302 (WO 2018/107173 Al). M.G.V.H. is a founder of Auron Therapeutics and is a member of the Scientific Advisory Board for Agios Pharmaceuticals, Aeglea Biotherapeutics and iTeos Therapeutics.